Alisa A. Lipski
Associate
An associate of the Houston, Texas based intellectual property law firm of Goldstein, Faucett & Prebeg, one of 10 patent litigation attorneys with the firm. Ms. Lipski's focus is on intellectual property protection, primarily patent infringement litigation and appeals. Her interest in intellectual property also extends to patent prosecution, particularly reexaminations and reissues in preparation for and during patent infringement litigation.
Education
- University of Texas at Austin - 2000 B.S. in Biochemistry
- University of Houston Law Center - 2003 J.D.
Experience
- Since starting with the firm in 2004, Ms. Lipski has participated in numerous patent litigation lawsuits seeking the recovery of patent infringement damages in federal Courts around the country, including the Eastern District of Texas. She has participated in numerous Markman hearings and has argued in front of the Federal Circuit. Major patent litigation lawsuits include contingency fee patent litigation against industry leaders in a variety of fields, including telecommunications and biotechnology.
Memberships
- Texas State Bar
- Licensed to practice before the United States Patent and Trademark Office
- Admitted to practice before the Federal Circuit Court of Appeals, and the Southern, Eastern and Western Districts of Texas
- Member of the AIPLA Litigation Committee
- Member of the Houston Bar Association
- Member of the Houston Intellectual Property Law Association
Representative Representation
Advanced Biological Laboratories (www.ablsa.com) is a biotech company founded in 2000 as a spin-off from the European academic research centre,
CRP-Santé, Luxembourg
. ABL's expertise lies within infectious diseases, with particular focus on resistance patterns and clinical outcome predictors for HIV-1, tuberculosis, hepatitis, malaria and human papillomavirus (HPV) infections. For ABL, Goldstein, Faucett & Prebeg has obtained a patent immunity agreement with
Stanford
University
, as well as a non-exclusive, royalty-bearing license agreement with Viralliance, Inc., a corporation which develops technologies to evaluate in vitro drug potency on patient’s derived viruses. GFP has also resolved several
U.S.
business disputes for ABL. Goldstein, Faucett & Prebeg continues to represent ABL in assertion of its
U.S.
patents against major commercial entities.
|